Altretamine

Summary

Altretamine (CHEMBL1455) is an approved small molecule (ATC L01XX03); indicated across 3 conditions including neoplasm and lymphoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01XX03
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 210.28 Da · C9H18N6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1455
Name	Altretamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2123
ChEBI	CHEBI:24564
ATC	L01XX03
Molecular formula	C9H18N6
Molecular weight	210.28
InChIKey	UUVWYPNAQBNQJQ-UHFFFAOYSA-N

SMILES: CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C

IUPAC name: 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine

Also known as: Altretamina, Altretamine, Hexalen, Hexamethylmelamine, Hexastat, NSC-13875, SID11110789, SID50103890, SID85230922, SID855523, SID90341558, ALTRETAMINE

Patent coverage: 24,493 distinct patent families (102,000 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Prelamin-A/C, RecQ-like DNA helicase BLM, Thyroid hormone receptor beta, Muscarinic acetylcholine receptor M1, Cytochrome P450 1A2, 3-hydroxyacyl-CoA dehydrogenase type-2, CREB-binding protein.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
THRB	8.8	Potency	1.6	nM	CHEMBL_ACT_4015939
HSD17B10	6.5	Potency	316.2	nM	CHEMBL_ACT_4881627
LMNA	6.1	Potency	794.3	nM	CHEMBL_ACT_3651435
CYP1A2	5.7	AC50	1995	nM	CHEMBL_ACT_6012060
P08482	5.55	Potency	2818	nM	CHEMBL_ACT_4857823
CYP1A2	5.4	IC50	4000	nM	CHEMBL_ACT_7622451

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
lymphoma	1	MONDO:0005062	EFO:0000574
sarcoma	1	MONDO:0005089	EFO:0000691

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002936	PHASE1	COMPLETED	Altretamine and Etoposide in Treating Patients With HIV-Related Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).